{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360004231519780096.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s12185-012-1186-7"}},{"identifier":{"@type":"URI","@value":"https://link.springer.com/content/pdf/10.1007/s12185-012-1186-7.pdf"}},{"identifier":{"@type":"URI","@value":"https://link.springer.com/article/10.1007/s12185-012-1186-7/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s12185-012-1186-7"}},{"identifier":{"@type":"PMID","@value":"23054649"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma"}],"dcterms:alternative":[{"@value":"Verlag Dr. Kovac, ISBN: 978-3-8300-6328-5, 98,80 €"}],"description":[{"notation":[{"@value":"High-dose chemotherapy followed by autologous stem cell transplantation (auto-SCT) is widely used as a salvage therapy in the treatment of refractory malignant lymphoma. To investigate the safety and feasibility of a high-dose MCNU, carboplatin, etoposide and cyclophosphamide (MCVC) regimen, we conducted a prospective multicenter trial. Thirty patients with relapsed/refractory/poor-risk non-Hodgkin lymphoma (NHL n = 27) or Hodgkin lymphoma (HD n = 3) were uniformly treated with an MCVC regimen and underwent auto-SCT. The median follow-up duration of the surviving patients was 67 months (56-133 months). The major toxicities were anorexia (94 %), diarrhea (80 %), nausea (79 %), febrile neutropenia (70 %), alopecia (67 %) and mucositis (60 %). Three patients developed severe left ventricular dysfunction, and two patients developed severe sinusoidal obstructive syndrome (SOS). Of these patients, two died without disease progression. Treatment-related mortality was 6.6 %. Late-onset adverse events including two cases of cytomegalovirus pneumonia and one of interstitial pneumonia were observed. In DLBCL (n = 13) and transformed FL (n = 2) patients, OS and EFS at 3 years were 72 and 46 %, respectively. These results suggest that the MCVC regimen followed by auto-SCT is a feasible and tolerable therapy for relapsed/refractory malignant lymphoma. However, cardiac toxicity due to high-dose cyclophosphamide and development of SOS can occur and should be carefully monitored. Further follow-up is needed to evaluate the long-term efficacy and safety of this regimen."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004231519779971","@type":"Researcher","foaf:name":[{"@value":"Yoshihiro Kameoka"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231519780100","@type":"Researcher","foaf:name":[{"@value":"Naoto Takahashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1420282801181687808","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"00359506"},{"@type":"NRID","@value":"1000000359506"},{"@type":"NRID","@value":"9000327095738"},{"@type":"NRID","@value":"9000384355430"},{"@type":"NRID","@value":"9000019018293"},{"@type":"NRID","@value":"9000290364317"},{"@type":"NRID","@value":"9000238231963"},{"@type":"NRID","@value":"9000001855611"},{"@type":"NRID","@value":"9000242743040"},{"@type":"NRID","@value":"9000396151507"},{"@type":"NRID","@value":"9000263031877"},{"@type":"NRID","@value":"9000240538365"},{"@type":"NRID","@value":"9000383839086"},{"@type":"NRID","@value":"9000376944090"},{"@type":"NRID","@value":"9000403514813"},{"@type":"NRID","@value":"9000272995509"},{"@type":"NRID","@value":"9000326647588"},{"@type":"NRID","@value":"9000397697452"},{"@type":"NRID","@value":"9000021924638"},{"@type":"NRID","@value":"9000258045404"},{"@type":"NRID","@value":"9000018840038"},{"@type":"NRID","@value":"9000019041559"},{"@type":"NRID","@value":"9000356657521"},{"@type":"NRID","@value":"9000257937318"},{"@type":"NRID","@value":"9000001934633"},{"@type":"NRID","@value":"9000398264679"},{"@type":"NRID","@value":"9000021357612"},{"@type":"NRID","@value":"9000308729476"},{"@type":"NRID","@value":"9000257871927"},{"@type":"NRID","@value":"9000241549021"},{"@type":"NRID","@value":"9000313627229"},{"@type":"NRID","@value":"9000291611662"},{"@type":"NRID","@value":"9000404148236"},{"@type":"NRID","@value":"9000021299387"},{"@type":"NRID","@value":"9000392826690"},{"@type":"NRID","@value":"9000007574460"},{"@type":"NRID","@value":"9000402436287"},{"@type":"NRID","@value":"9000265262213"},{"@type":"NRID","@value":"9000361685860"},{"@type":"NRID","@value":"9000006077974"},{"@type":"NRID","@value":"9000408657291"},{"@type":"NRID","@value":"9000257870587"},{"@type":"NRID","@value":"9000021933392"},{"@type":"NRID","@value":"9000413764234"},{"@type":"NRID","@value":"9000276434814"},{"@type":"NRID","@value":"9000362196009"},{"@type":"NRID","@value":"9000402492459"},{"@type":"NRID","@value":"9000356561243"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/y-t-s"}],"foaf:name":[{"@value":"Kenichi Ishizawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231519779844","@type":"Researcher","foaf:name":[{"@value":"Yuichi Kato"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231519779977","@type":"Researcher","foaf:name":[{"@value":"Jugo Ito"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231519780101","@type":"Researcher","foaf:name":[{"@value":"Osamu Sasaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231519779984","@type":"Researcher","foaf:name":[{"@value":"Kazunori Murai"}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326207132416","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"20347214"},{"@type":"NRID","@value":"1000020347214"},{"@type":"NRID","@value":"9000001559981"},{"@type":"NRID","@value":"9000003891883"},{"@type":"NRID","@value":"9000257905312"},{"@type":"NRID","@value":"9000018705522"},{"@type":"NRID","@value":"9000019959593"},{"@type":"NRID","@value":"9000240055910"},{"@type":"NRID","@value":"9000240538370"},{"@type":"NRID","@value":"9000265535207"},{"@type":"NRID","@value":"9000258037572"},{"@type":"NRID","@value":"9000019974934"},{"@type":"NRID","@value":"9000258040182"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0069810"}],"foaf:name":[{"@value":"Hideyoshi Noji"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231519780096","@type":"Researcher","foaf:name":[{"@value":"Makoto Hirokawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231519779968","@type":"Researcher","foaf:name":[{"@value":"Katsusi Tajima"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231519779973","@type":"Researcher","foaf:name":[{"@value":"Tsutomu Shichishima"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231519779842","@type":"Researcher","foaf:name":[{"@value":"Yoji Ishida"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231519779979","@type":"Researcher","foaf:name":[{"@value":"Hideo Harigae"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004231519779978","@type":"Researcher","foaf:name":[{"@value":"Kenichi Sawada"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09255710"},{"@type":"EISSN","@value":"18653774"}],"prism:publicationName":[{"@value":"International Journal of Hematology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2012-10-01","prism:volume":"96","prism:number":"5","prism:startingPage":"624","prism:endingPage":"630"},"reviewed":"false","dc:rights":["https://www.springer.com/tdm","https://www.springer.com/tdm"],"url":[{"@id":"https://link.springer.com/content/pdf/10.1007/s12185-012-1186-7.pdf"},{"@id":"https://link.springer.com/article/10.1007/s12185-012-1186-7/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s12185-012-1186-7"}],"createdAt":"2012-10-01","modifiedAt":"2022-07-29","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Hematology","dc:title":"Hematology"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000782125095040","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"22591067"},{"@type":"JGN","@value":"JP22591067"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22591067/"}],"notation":[{"@language":"ja","@value":"PNHにおけるペプチドワクチンによる免疫療法の可能性"},{"@language":"en","@value":"Basic study of immunotherapy with peptide vaccine in PNH"}]},{"@id":"https://cir.nii.ac.jp/crid/1040000782212632960","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"24590677"},{"@type":"JGN","@value":"JP24590677"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-24590677/"}],"notation":[{"@language":"ja","@value":"県内全リンパ腫登録を基盤として原発の影響と低頻度亜型の解析を行う臨床病理学的研究"},{"@language":"en","@value":"Clinicopathological features of malignant lymphoma in Miyagi study"}]},{"@id":"https://cir.nii.ac.jp/crid/1040282257101748480","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"22591044"},{"@type":"JGN","@value":"JP22591044"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22591044/"}],"notation":[{"@language":"ja","@value":"新たな手法によるPNHクローンの拡大抑制に関する基礎的検討"},{"@language":"en","@value":"Basic stydies of suppression to expansion of PNH colne by new methods"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011144252341888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145189382400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effectiveness of high-dose MCNU therapy and hematopoietic stem cell autografts treatment of childhood acute leukemia/lymphoma with high-risk features"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145333897856","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146616680576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285714669991168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Upfront high-dose chemotherapy combined with autologous stem cell transplantation: Potential survival benefit for patients with high-risk diffuse large B-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621150452480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621268471808","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nonparametric Estimation from Incomplete Observations"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095295837312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Autologous Transplantation for Diffuse Aggressive Non-Hodgkin’s Lymphoma in Patients Never Achieving Remission: A Report from the Autologous Blood and Marrow Transplant Registry"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848658327289728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855568809581440","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045667836160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapy‐Sensitive Relapsed and Primary Refractory Non‐Hodgkin’s Lymphoma: Identification of Major Prognostic Groups"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994353302272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Feasibility and Efficacy of High-Dose Melphalan, Cyclophosphamide, Etoposide, and Dexamethasone (LEED) Chemotherapy with or without Rituximab Followed by Autologous Stem Cell Transplantation for Aggressive and Relapsed Non-Hodgkin's Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994822078208","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin’s lymphoma patients: comparative analysis of efficacy and toxicity"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469156278656","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470409206912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The toxicity of busulphan and cyclophosphamide as the preparative regimen for bone marrow transplantation"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944550220032","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893378957568","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893576063232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin’s lymphoma: results of outpatient treatment in community cancer centers"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368531988352","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107370440416768","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320881107200","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794737205888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795392865920","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Risk Model for Thrombocytopenia Requiring Platelet Transfusion After Cytotoxic Chemotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268929491200","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1390016339424544000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy and Safety of Synbiotics in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Randomized, Double-blinded, Placebo-controlled Pilot Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680398354048","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Prognostic factors in patients with relapsed or refractory diffuse large B-cell lymphoma who underwent autologous stem-cell transplantation"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s12185-012-1186-7"},{"@type":"KAKEN","@value":"PRODUCT-13549515"},{"@type":"KAKEN","@value":"PRODUCT-14693034"},{"@type":"KAKEN","@value":"PRODUCT-13548444"},{"@type":"OPENAIRE","@value":"doi_dedup___::acbe40825b64421f6ab6a25f775b8bb4"},{"@type":"CROSSREF","@value":"10.3892/ol.2017.6589_references_DOI_Eo5sH16yHTLEtjtC6zOHcMgiIRM"},{"@type":"CROSSREF","@value":"10.7889/hct.5.93_references_DOI_Eo5sH16yHTLEtjtC6zOHcMgiIRM"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.1314-22_references_DOI_Eo5sH16yHTLEtjtC6zOHcMgiIRM"}]}